Lung Cancer Clinical Trial

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Summary

The purpose of this study is to determine the safety and efficacy of BMS-986207 in combination with nivolumab and ipilimumab as first-line treatment for participants with stage IV non-small cell lung cancer (NSCLC).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed metastatic 1L Stage IV non-small cell lung cancer (NSCLC) of squamous or nonsquamous histology
No prior systemic anti-cancer treatment given as primary therapy for advanced or metastatic NSCLC
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 20 unstained slides of tumor tissue obtained during screening or prior to enrollment
Life expectancy of at least 3 months at the time of first dose

Exclusion Criteria:

Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or c-ros oncogene 1 (ROS-1) mutations which are sensitive to available targeted inhibitor therapy. Participants with nonsquamous histology and unknown EGFR, ALK, or ROS-1 status are also excluded
Participants with known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF) V600E mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown or indeterminate BRAF mutation status are eligible.
Untreated central nervous system metastases
Leptomeningeal metastases (carcinomatous meningitis)
Concurrent malignancy requiring treatment
Active, known, or suspected autoimmune disease
Interstitial lung disease
Uncontrolled or significant cardiovascular disease

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

180

Study ID:

NCT05005273

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 72 Locations for this study

See Locations Near You

Compassionate Cancer Care Medical Group
Fountain Valley California, 92708, United States More Info
Eric Lee, Site 0051
Contact
Local Institution
Fort Myers Florida, 33901, United States More Info
Site 0070
Contact
Local Institution
Gainesville Florida, 32610, United States More Info
Site 0073
Contact
Mid Florida Hematology and Oncology Center
Orange City Florida, 32763, United States More Info
Santosh Nair, Site 0036
Contact
386-353-1915
Local Institution
Pensacola Florida, 32504, United States More Info
Site 0045
Contact
Local Institution
Port Saint Lucie Florida, 34952, United States More Info
Site 0029
Contact
Local Institution
Saint Petersburg Florida, 33705, United States More Info
Site 0068
Contact
Local Institution
Tallahassee Florida, 32308, United States More Info
Site 0069
Contact
Local Institution
West Palm Beach Florida, 33401, United States More Info
Site 0071
Contact
Saint Alphonsus Regional Medical Center
Boise Idaho, 83706, United States More Info
Bobby Chawla, Site 0081
Contact
208-367-3131
Local Institution
Coeur d'Alene Idaho, 83214, United States More Info
Site 0077
Contact
Local Institution
Edgewood Kentucky, 41017, United States More Info
Site 0074
Contact
Local Institution
Ann Arbor Michigan, 48109, United States More Info
Site 0002
Contact
Local Institution
Brooklyn New York, 11220, United States More Info
Site 0049
Contact
Local Institution
Charleston South Carolina, 29414, United States More Info
Site 0012
Contact
$Form.Name
Milwaukee Wisconsin, 53226, United States More Info
Johnathan Thompson, Site 0053
Contact
Local Institution - 0009
Pergamino Buenos Aires, 2700, Argentina More Info
Site 0009
Contact
Local Institution
Rosario Santa FE, S2000, Argentina More Info
Site 0054
Contact
Local Institution
Buenos Aires , 1061, Argentina More Info
Site 0062
Contact
Local Institution
Buenos Aires , 1125, Argentina More Info
Site 0021
Contact
Local Institution
Buenos Aires , C1122, Argentina More Info
Site 0048
Contact
Local Institution
Buenos Aires , C1280, Argentina More Info
Site 0011
Contact
Local Institution
San Juan , 5400, Argentina More Info
Site 0057
Contact
Local Institution
Orange New South Wales, 2800, Australia More Info
Site 0063
Contact
Local Institution
Wahroonga New South Wales, , Australia More Info
Site 0056
Contact
Local Institution
Douglas Queensland, 4814, Australia
Local Institution
Warrnambool Victoria, 3280, Australia More Info
Site 0052
Contact
Local Institution
Charleroi , 6000, Belgium More Info
Site 0040
Contact
Local Institution
Mechelen , 2800, Belgium More Info
Site 0034
Contact
Local Institution
Mons , 7000, Belgium More Info
Site 0043
Contact
Local Institution - 0019
Sint-Niklaas , 9100, Belgium More Info
Site 0019
Contact
Local Institution
Vina del Mar Valparaiso, 25200, Chile More Info
Site 0035
Contact
Local Institution
Vina del Mar Valparaiso, 25205, Chile More Info
Site 0015
Contact
Local Institution - 0050
Santiago , 83200, Chile More Info
Site 0050
Contact
Local Institution
Limoges , 87042, France More Info
Site 0037
Contact
Local Institution
Nantes , 44093, France More Info
Site 0030
Contact
Local Institution
Pessac , 33604, France More Info
Site 0044
Contact
Local Institution
Rouen , 76000, France More Info
Site 0016
Contact
Local Institution
Saint Priest en Jarez , 42271, France More Info
Site 0031
Contact
Local Institution
Suresnes , 92150, France More Info
Site 0013
Contact
Local Institution
Toulon , 83056, France More Info
Site 0042
Contact
Local Institution - 0005
Gauting Bayern, 82131, Germany More Info
Site 0005
Contact
Local Institution
Frankfurt , 60431, Germany More Info
Site 0022
Contact
Local Institution
Gera , 7548, Germany More Info
Site 0017
Contact
Local Institution - 0025
Mainz , 55131, Germany
Local Institution
Muenchen , 81925, Germany More Info
Site 0023
Contact
Local Institution
Wiesbaden , 65199, Germany More Info
Site 0059
Contact
Local Institution
Torokbalint , 2045, Hungary
Local Institution
Haifa , 33394, Israel More Info
Site 0064
Contact
Local Institution
Jerusalem , 91031, Israel More Info
Site 0061
Contact
Local Institution - 0079
Jerusalem , 91200, Israel More Info
Site 0079
Contact
Local Institution
Jerusalem , 91200, Israel More Info
Site 0078
Contact
Local Institution
Bari , 70124, Italy More Info
Site 0027
Contact
Local Institution - 0007
Bologna , 40138, Italy
Local Institution
Milano , 20133, Italy More Info
Site 0047
Contact
Local Institution
Monza , 20900, Italy More Info
Site 0039
Contact
Local Institution
Naples , 80131, Italy More Info
Site 0028
Contact
Local Institution
Padova , 35128, Italy More Info
Site 0001
Contact
Local Institution
Rozzano , 20089, Italy More Info
Site 0020
Contact
Local Institution
Bydgoszcz , 85-79, Poland More Info
Site 0024
Contact
Local Institution - 0003
Lodz , 93-33, Poland More Info
Site 0003
Contact
Local Institution
Otwock , 05-40, Poland More Info
Site 0038
Contact
Local Institution
Szczecin , 70-45, Poland More Info
Site 0058
Contact
Local Institution - 0041
Alicante , 3010, Spain More Info
Site 0041
Contact
Local Institution
Barcelona , 08017, Spain More Info
Site 0026
Contact
Local Institution
Barcelona , 08028, Spain More Info
Site 0075
Contact
Local Institution
Barcelona , 08908, Spain More Info
Site 0006
Contact
Local Institution
Jaen , 23007, Spain More Info
Site 0046
Contact
Local Institution
Madrid , 28040, Spain More Info
Site 0032
Contact
Local Institution
Majadahonda , 28220, Spain More Info
Site 0033
Contact
Local Institution
Istanbul , 34010, Turkey More Info
Site 0076
Contact
Local Institution - 0066
Istanbul , 34098, Turkey More Info
Site 0066
Contact
Local Institution - 0065
Izmir , 35575, Turkey More Info
Site 0065
Contact
Local Institution
Samsun , 55200, Turkey More Info
Site 0067
Contact
Local Institution
Yuregir , 113, Turkey More Info
Site 0072
Contact

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

180

Study ID:

NCT05005273

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.